<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295787</url>
  </required_header>
  <id_info>
    <org_study_id>2014D006212</org_study_id>
    <nct_id>NCT02295787</nct_id>
  </id_info>
  <brief_title>Intranasal Ketamine for Late-Life Depression and Suicidal Ideation</brief_title>
  <official_title>Intranasal Ketamine for Late-Life Depression and Suicidal Ideation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators of this study plan to investigate the feasibility and efficacy of repeated&#xD;
      doses of intranasal ketamine in severely depressed patients who are at least 65 years of age&#xD;
      and experiencing suicidal ideation. The results of the study could lead to development of new&#xD;
      strategies for treating depression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No funding&#xD;
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HDRS)</measure>
    <time_frame>Up to 4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Depression</condition>
  <condition>Suicide</condition>
  <condition>Suicidal Ideation</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal Ketamine 50mg administered six times over three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intranasal saline solution administered six times over three weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Intranasal ketamine for late-life depression and suicidal ideation.</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1) be ≥65 years old, 2) provide written informed consent, 3) meet criteria for a primary&#xD;
        psychiatric diagnosis of major depressive disorder according to the Structured Clinical&#xD;
        Interview for DSM-IV (SCID) and have a HDRS28 total score ≥20; depression may have started&#xD;
        at any time point in their life, and certain co-morbid diagnoses (e.g., anxiety disorders)&#xD;
        will be allowed insofar as they are not the primary psychiatric diagnosis, 4) have a&#xD;
        history of ≥2 failed medication trials during the current episode (per the Massachusetts&#xD;
        General Hospital Antidepressant Treatment History Questionnaire; MGH ATRQ), 5) endorse&#xD;
        suicidal ideation for more than 2 months, per the Columbia Suicide Severity Rating Scale&#xD;
        (C-SSRS) and have a HDRS28 suicide item score ≥1 (thoughts that life isn't worth living),&#xD;
        6) be on a stable antidepressant regimen for ≥14 days prior to Study Phase II, 7) maintain&#xD;
        a treating psychiatrist who is in agreement with study participation, and 8) have a&#xD;
        reliable chaperone accompany them home following the completion of the intranasal&#xD;
        administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded if any of the following criteria are met: 1) Delirium or&#xD;
             dementia diagnosis, 2) unstable medical illness, 3) history of clinically significant&#xD;
             cardiovascular disease or electrocardiogram (EKG) findings, or medical conditions that&#xD;
             put the patient at risk for possible cardiac side effects, 4) history of multiple&#xD;
             adverse drug reactions, 5) current/past history of psychotic disorders or&#xD;
             homicidality, 6) active substance use disorders (except nicotine and caffeine) within&#xD;
             the past six months, positive urine toxicology screen, or past history of ketamine&#xD;
             abuse, 7) requirement of excluded medications (narcotics, barbiturates, theophylline,&#xD;
             or St. John's Wort), or 8) concurrent or recent participation in other research&#xD;
             studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn F Ionescu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Dawn F Ionescu</investigator_full_name>
    <investigator_title>Assistant in Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Suicide</keyword>
  <keyword>Suicidal Ideation</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Late-Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Suicide</mesh_term>
    <mesh_term>Suicidal Ideation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

